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Abstract  
Objective : Ovarian steroid cell tumor (SCT) is a rare tumor with steroid-producing ability. We re-
port a 22-year-old woman with secondary amenorrhea and hirsutism caused by an ovarian SCT-not 
otherwise specified (NOS), who underwent successfully laparoscopic resection of the tumor.  
Case report : A 22-year-old null gravida woman presented to a hospital, having amenorrhea for 18 
months and increasing facial hair. Physical examination revealed obesity (body mass index, 37.3 kg/
m2) with evident facial and trunk hair. Total and free serum testosterone, and dehydroepiandros-
terone sulfate levels were found to be elevated. Levels of serum adrenocorticotropic hormone, go-
nadotropins, cortisol, aldosterone, and ovarian steroids were observed to be within reference inter-
vals. Although polycystic ovaries were not found, a hyperechogenic solid tumor (3 cm) was 
detected on transvaginal ultrasonography. Laparoscopic resection of the tumor was per-
formed. One month post-surgery, total and free testosterone levels were observed to have de-
creased, and menstruation resumed two months thereafter. The patient was histologically diag-
nosed with ovarian SCT-NOS. Expression of ovarian steroidogenic enzymes, which are related to 
hyperandrogenism, was observed. No disease recurrence has been reported for more than 5 years 
post-surgery.
Key words : amenorrhea, ovarian tumor, steroid cell tumor not other specified, hyperandrogenism, 
laparoscopic surgery
Introduction
Ovarian steroid cell tumor (SCT) is a very rare 
entity, comprising 0.1% of all ovarian tumors1). 
Ovarian SCTs are of three subtypes based on the 
source of cell origin : stromal luteoma, Leydig cell 
tumor, and not otherwise specified (NOS)2). SCT-
NOS, which accounts for over 50% of the ovarian 
SCTs, derives from an indeterminate lineage of ovar-
ian tissue3). All subtypes of SCT have the potential 
of producing steroid hormones such as androgen, 
estrogen, and cortisol3). Androgen producing SCT-
NOS causes various virilizing symptoms including 
hirsutism, baldness, and amenorrhea1). Here, we 
report on a 22-year-old female with secondary 
amenorrhea and hirsutism caused by androgen-pro-
ducing SCT-NOS. She was treated successfully 
with laparoscopic resection of the tumor. Addition-
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ally, we examined the immune expression of steroid 
synthetic enzymes which are involved in androgen 
synthesis. We obtained informed consent from the 
patient to publish this case report.
Case presentation
A 22-year-old null gravida woman presented 
with amenorrhea for 18 months and increasing facial 
hair (Fig. 1). She was referred to our hospital as a 
possible case of endocrine abnormality, presumably 
polycystic ovary syndrome (PCOS). Since men-
arche at 11 years old, she never had regular men-
struation. She was 148 cm tall and weighed 78 
kg ; her body mass index (BMI) was 37.3 kg/
m2. Waist and hip circumferences were recorded as 
101 and 110 cm, respectively, with a waist to hip ra-
tio of 0.918. Systolic and diastolic blood pressure 
and heart rate were observed to be 141/102 mmHg 
and 86/min, respectively. She presented with hir-
sutism of the face and trunk ; however, no remark-
able signs of hoarseness, frontotemporal baldness, 
or clitoromegaly were observed. Pelvic examina-
tion, performed manually for reasons of body habi-
tus, was reported as unremarkable. Biochemical 
and hormonal data are shown in Table 1. Biochem-
ical data shows the levels of serum uric acid and tri-
glyceride were as high as 6.8 mg/dl and 419 mg/dl, 
respectively. For glucose tolerance and insulin re-
sistance, the levels of fasting-plasma glucose and 
HbA1c were within reference intervals. Further-
more, fasting immunoreactive insulin and homeo-
static model assessment index were reported to be 
as high as 32.8 µIU/mL and 6.8, respectively. Se-
rum adrenocorticotropic hormone, gonadotropins, 
cortisol, aldosterone, and ovarian steroids were 
found within reference intervals. Total and free se-
rum testosterone, and dehydroepiandrosterone sul-
fate levels were found to be as high as 1.3 ng/mL 
(reference interval, 0.15-0.44 ng/mL), 4.5 pg/mL 
(reference interval, < 2.7 pg/mL), and 332 µg/dL 
(reference interval, 73-322 µg/dL), respective-
ly. Transvaginal ultrasound identified a 3.0 × 2.3-
cm left ovarian solid mass without sign of polycystic 
ovaries (Fig. 2). Magnetic resonance imaging with 
contrast medium confirmed the presence of a well-
enhanced left ovarian tumor (Fig. 3). We diagnosed 
an androgen-producing ovarian tumor and metabolic 
syndrome. Expression levels of tumor markers for 
alpha-fetoprotein (AFP), carcinoembryonic antigen 
(CEA), cancer antigen 19-9 (CA19-9), CA125, and 
squamous cell carcinoma antigen (SCC) were within 
reference intervals. On diagnosis of androgen-pro-
Fig. 1. Picture shows facial hirsutism.
Table 1. Biochemical and hormonal data
Total protein 7.5 g/dl (6.7-8.3 g/dl)
Alb 4.2 g/dl (3.8-5.2 g/dl)
AST 12 U/l (10-40 U/l)
ALT 17 U/l (5-40 U/l)
γGTP 24 U/l (< 30 U/l)
BUN 9 mg/dl (8-22 mg/dl)
Creatinine 0.42 mg/dl (0.47-0.79 mg/dl)
UA 6.8 mg/dl (2.5-7.0 mg/dl)
Na 142 mmol/l (136-147 mmol/l)
K 4.1 mmol/l (3.6-5.0 mmol/l)
Cl 106 mmol/l (93-109 mmol/l)
Ca 9.3 mg/dl (8.5-10.2 mg/dl)
Triglyceride 419 mg/dl (50-149 mg/dl)
Total cholesterol 199 mg/dl (150-219 mg/dl)
LDL-cholesterol 137 mg/dl (70-139 mg/dl)
HDL-cholesterol 36 mg/dl (40-96)
Fasting glucose 84 mg/dl (70-109)
HbA1c 5.3% (4.6-6.2)
Fasting insulin 32.8 μIU/ml (1.84-12.2 μIU/ml)
HOMA-IR 6.8 (< 1.6)
ACTH 8.5 pg/ml (7.2-63.3 pg/ml)
Cortisol 1.7 μg/dl (6.24-18.0 μg/dl)
LH 2.3 mIU/ml (1.76-10.24 mIU/ml)
FSH 4.9 mIU/ml (3.01-14.72 mIU/ml)
PRL 25.7 ng/ml (4.91-29.3 ng/ml)
Estradiol 58 pg/ml (28.8-196.8 pg/ml)
Progesterone 0.82 ng/ml (< 0.28 ng/ml)
Total testosterone 1.3 ng/ml (0.15-0.44 ng/ml)
Free testosterone 4.5 pg/ml (< 2.7 pg/ml)
DHEA-S 332 μg/dl (73-322 μg/dl)
HOMA-IR :  homeostasis model assessment for insulin 
resistance, DHEA-S : dehydroepiandrosterone sulfate. 
Reference intervals are shown in parentheses.
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ducing ovarian tumor, we performed laparoscopic re-
section. In the peritoneal cavity, no ascites was ob-
served, and peritoneal washing was collected for 
cytological examination. Laparoscopic findings re-
vealed that the left ovary was slightly enlarged with 
no sign of rupture or metastasis in the abdominal 
cavity. The left ovary was excised and a well-cir-
cumscribed soft hemorrhagic mass was carefully re-
moved using scissors and forceps (Fig. 4). Cyto-
logical examination of peritoneal washing was 
negative. In this case, we did not perform rapid in-
traoperative pathological examination ; subsequent 
treatment was decided based on permanent-section 
pathology. The excised surface of the specimen ap-
peared yellow with a solid hemorrhagic mass. Mi-
croscopic findings revealed tumor cells arranged in a 
diffuse pattern or columns, or arranged in nets, and 
the cell morphology was observed to be polygonal 
with abundant cytoplasm (Fig. 5). As crystals of 
Reinke were not observed, the pathological diagno-
sis was SCT-NOS. Average mitotic activity was 
found to be 1.8 over 10 high power fields. No signs 
of necrosis, hemorrhage, and nuclear atypia were 
observed. We analyzed the expression of steroido-
genic enzymes of the tumor by immunohistochemis-
try. Different expressions of the steroidogenic en-
zymes in the specimen are illustrated in Table 2. 
Fig. 2. Transvaginal ultrasonography findings : Ar-
row indicates the ovarian tumor.
Fig. 3. MRI findings : Arrows indicate the ovarian tumor.
Fig. 4. Laparoscopic operative procedure : Images show laparoscopic resection of the left ovarian tumor (a, b, c, d, e, 
and f).
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Immunoexpression of ovarian steroidogenic en-
zymes such as 3-β-hydroxysteroid dehydrogenase 
(3-β-HSD), P450c17, 5-α-reductase type 1/2, 
17-β-HSD 5, and 17-β-HSD 1 were observed to be 
high, whereas the expression of P450 side-chain 
cleavage (P450scc) enzyme, aromatase, and steroid 
sulfatase were undetected. On the other hand, ad-
renal steroidogenic enzymes such as P450c21, dehy-
droepiandrosterone sulfotransferase (DHEA-ST), 
steroid 11-β-hydroxylase (CYP11B1), and aldoste-
rone synthase (CYP11B2) were not detected. As 
ovarian SCT-NOS is classified as a borderline malig-
nancy, we offered an additional operation of ipsilater-
al oophorectomy. However, she did not agree to 
additional surgery and wanted diligent follow-
up. After the operation, total and free testosterone 
levels were found to have rapidly decreased while 
menstruation was reported to have resumed sponta-
neously 2 months thereafter (Fig. 6). No recur-
rence of disease has been observed for more than 5 
years post-surgery.
Discussion
We encountered a case of a 22-year-old woman 
who presented with amenorrhea and virilization due 
Fig. 5. Pathological findings : Macroscopic appearance (A). Microscopic findings (B : low power field, C : high 
power field).
Table 2. Immunoexpression of steroidogenic enzymes
Positive expression Negative expression
3 β-HSD P450scc
P450c17 aromatase




HSD : hydroxysteroid dehydrogenase, scc : side 
chain cleavage, DHEA-ST : dehydroepiandrosterone 
sulfotransferase, CYP11B1 : steroid 11 β-hydroxylase, 
CYP11B2 : aldosterone synthase. *, adrenal steroido-
genic enzymes.
Fig. 6. Chart of clinical course 
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to an androgen-producing ovarian tumor. Laparo-
scopic partial resection of the ovarian tumor was 
performed, and histopathological examination re-
vealed ovarian SCT-NOS.
It is crucial to differentiate SCT-NOS from oth-
er types of steroid cell tumors, such as stromal lute-
oma or Leydig cell tumors. Leydig cell tumors are 
commonly present in a hilar location and have cyto-
plasmic Reinke crystals. Stromal luteoma is com-
monly located in the ovarian stroma and is associat-
ed with stromal hyperthecosis. In the present 
case, as pathological findings such as cytoplasmic 
Reinke crystals and stromal luteoma were absent, 
this case was diagnosed as SCT-NOS. Moreover, 
while immunohistochemical staining with inhibin 
and calretinin is useful to differentiate among other 
non-sex cord tumors4), staining for such tumors was 
not performed.
Although the majority of ovarian sex cord-stromal 
tumors, including ovarian SCT, are benign, ovarian 
SCT-NOS exhibits a malignant potential that has been 
reported in approximately one-third of all cases1,2). 
Further, ovarian SCT-NOS is classified as a border-
line malignancy. Standard treatment for women 
with no pregnancy intention is hysterectomy and bi-
lateral salpingo-oophorectomy with omentecto-
my. On the other hand, those women who desire 
future fertility can be treated with ipsilateral adnex-
ectomy and omentectomy by laparotomy. In the 
present case, as she wanted to have a child, partial 
resection of the tumor was performed by laparo-
scopic surgery.
Laparoscopic surgery is a common procedure 
for benign ovarian lesions. Recently, there have 
been reports about laparoscopic surgery for ovarian 
tumors of borderline malignancy including SCT-
NOS. As per our literature survey, there have been 
only 11 cases of SCT-NOS who underwent laparo-
scopic surgery5-16). Many patients undergoing lapa-
roscopic surgery have opted for oophorectomy, and 
only three cases have been operated by partial re-
section5,7,10). Patients who were treated by laparo-
scopic partial resection were 30 years, 16 years, and 
23 years old ; all were considered to be in early 
stage of their disease. Although the follow-up pe-
riod after surgery was within three years for those 
patients, there was no recurrence of the disease.
Since ovarian SCT-NOS is rare and standard 
treatments have not been established, treatment 
strategies need to be determined with reference to 
pathological risk factors. Hayes and Scully report-
ed that poor prognostic factors for SCT-NOS 
are : tumor size > 7 cm, presence of 2 or more mi-
toses, presence of necrosis, hemorrhage, and grade 
2 or 3 nuclear atypia1). In this case, according to 
the Hayes’s criteria, none of the risk factors were 
observed. Thus, the tumor was not considered to 
be aggressive. Furthermore, the patient had care-
ful follow-up with no sign of recurrence even 5 years 
after surgery.
We evaluated the origin of increased serum tes-
tosterone levels by immunostaining steroidogenic 
enzymes. Ovarian steroidogenic enzymes, such as 
3 β-HSD, P450c17, 5 α-reductase 1/2, 17 β HSD 5, 
and 17 β HSD 1, were significantly expressed in the 
tumor cells. Our result was consistent with a tes-
tosterone-synthesizing tumor. However, since the 
expression of P450scc was scarcely observed, it was 
unlikely that steroidogenesis was active in the tu-
mor itself. Furthermore, as aromatase and steroid 
sulfatase were not expressed in the tumor, estrogen 
synthesis ability was considered to be low. These 
results suggested ovarian-derived hyperandrogen-
ism with normal ovarian steroidogenesis. On the 
other hand, although cases showing Cushing’s syn-
drome had been reported in ovarian SCT-NOS1,17), 
adrenal-specific steroidogenic enzymes such as 
P450c21, DHEA-ST, and CYP11B1/2 were not found 
to be expressed in this case. This indicates that 
adrenocortical hormone was not being synthesized.
Differential diagnosis of female virilization is 
essential18). There is female virilization by andro-
gen excess originating from the adrenal gland or 
ovary19). Adrenal hyperandrogenemia is caused by 
primary adrenal tumors, adrenocorticotropic hor-
mone-producing tumors such as Cushing disease, or 
congenital adrenal hyperplasia. Conversely, ovarian 
hyperandrogenism is caused by PCOS or androgen-
producing tumors of the ovary. In the present case, 
there were no findings of adrenal hyperandrogenism 
and no sign of polycystic ovary. Subsequently, we 
did find a solid ovarian tumor, which may produce 
androgens.
Clinical symptoms induced by steroid hormones 
that are derived from ovarian SCT-NOS are crucial 
for diagnosis. It has been reported that ovarian 
SCT-NOS synthesizes diverse steroid hormones 
such as androgen, estrogen, and cortisol1). The fre-
quency of hyperandrogenism induced by the tumor 
is reported to be 56% to 77%1,20). Thus, most pa-
tients show clinical symptoms of virilization such as 
hirsutism, hoarseness, and frontal baldness1). Hy-
perandrogenism also affects ovarian follicle develop-
ment and causes anovulation followed by amenor-
rhea1). There has been a report on primary 
amenorrhea with ovarian SCT-NOS in a 16-year old 
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female patient7).
In this case, Cushing syndrome was potential 
candidate for differential diagnosis. The frequency 
of Cushing syndrome caused by cortisol production 
from ovarian SCT-NOS is reported to be around 
10%1,20). Our present patient suffered from obesity, 
hypertension, and dyslipidemia, which met the crite-
ria for metabolic syndrome and amenorrhea. Al-
though these symptoms were consistent with Cush-
ing syndrome, serum cortisol was found to be within 
the reference interval. Moreover, in the present 
study, we confirmed that none of the steroidogenic 
enzymes related to cortisol synthesis were ex-
pressed in the tumor. This result aligns with the 
average level of serum cortisol in the patient.
In summary, the ovarian SCT-NOS is a rare tu-
mor that produces steroid hormones and causes vir-
ilization and menstrual irregularity. When patients 
are of reproductive age, fertility preservation should 
be considered, depending on the degree of malig-
nancy. If fertility-sparing surgery is performed, pa-
tients must be followed-up carefully.
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